ArticleBiomaterials research2023
Mn-single-atom nano-multizyme enabled NIR-II photoacoustically monitored, photothermally enhanced ROS storm for combined cancer therapy.
Article in Biomaterials research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 23 citations in OpenAlex.
- Single-atom nanozymes in nanomedicine: catalytic precision, mechanistic insights, and translational opportunities.Chemical science · 2026Review
- Innovative Strategies to Overcome Stability Challenges of Single-Atom Nanozymes.Nano-micro letters · 2026Review
- Engineered nanomedicine triggering ROS storms for enhanced cancer therapeutics.Regenerative biomaterials · 2026Review
- Camouflaged membrane-bridged radionuclide/Mn single-atom enzymes target lipid metabolism disruption to evoke antitumor immunity.Military Medical Research · 2025Article
- Closed-loop cascade nanozyme strategy for mutually reinforced catalytic and mild-temperature photothermal therapeutic effects.Journal of nanobiotechnology · 2025Article
- Conversion therapy strategy: A novel GPC3-targeted multimodal organic phototheranostics platform for mid-late-stage hepatocellular carcinoma.Materials today. Bio · 2025Article
- The Potential of Photoacoustic Imaging in Detecting and Managing Complex Wounds.Biomaterials research · 2025Review
- (Iso)quinoline-Modified Aza-Boron-Dipyrromethenes Near-Infrared-II Fluorescence/Photoacoustic Nanotheranostics for Cervical Tumor Photothermal Therapy.Biomaterials research · 2025Article
- Advancements in Antioxidant-Based Therapeutics for Spinal Cord Injury: A Critical Review of Strategies and Combination Approaches.Antioxidants (Basel, Switzerland) · 2024Review
- Preparation and Application of Carbon Dots Nanozymes.Antioxidants (Basel, Switzerland) · 2024Review
- Metallic Copper-Based Dual-Enzyme Biomimetic Nanoplatform for Mild Photothermal Enhancement of Anticancer Catalytic Activity.Biomaterials research · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 2 countries.
Funding
Abstract
rationaleTo realize imaging-guided multi-modality cancer therapy with minimal side effects remains highly challenging.
methodsWe devised a bioinspired hollow nitrogen-doped carbon sphere anchored with individually dispersed Mn atoms (Mn/N-HCN) via oxidation polymerization with triton micelle as a soft template, followed by carbonization and annealing. Enzyme kinetic analysis and optical properties were performed to evaluate the imaging-guided photothermally synergized nanocatalytic therapy.
resultsSimultaneously mimicking several natural enzymes, namely peroxidase (POD), catalase (CAT), oxidase (OXD), and glutathione peroxidase (GPx), this nano-multizyme is able to produce highly cytotoxic hydroxyl radical (•OH) and singlet oxygen (
conclusionsThis study not only demonstrates a new method for effective cancer diagnosis and therapy but also provides new insights into designing multi-functional nanozymes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.